Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-10-30
Ethical passes the values gate
Price80.26 USD
Fair value72.20
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markup67.30+19.3% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-02Read Markdown67.12+19.6% to today Markup gives way to Markdown
2026-08-28Read Markup70.34+14.1% to today ✓Distribution gives way to Markup after a 23% rise in 8 weeks
2026-07-02Read Distribution57.08+40.6% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Exponent, Inc. holds its Markup at $80.26. The statistical read favours the sellers, held for 90 days.
As held on the ledger · 2026-10-30
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 90 days
Price at the screen
$80.26
Valuation
32.80 trailing · 26.89 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.70
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.65%
Below 33%
Interest-bearing debt is just 10.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
45.87%
Below 49%
Money owed to the company is 45.9% of assets, under the 49% limit.
Pass
Revenue purity
1.60%
Below 5%
Only 1.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Exponent, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 11%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-30. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EXPO's ethical verdict changes
Today EXPO passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. The price runs 10.0% above the base estimate.
Third-party analyst targets: 3 covering, consensus None. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Science consultancy with strong returns but thin upside
Think of Exponent as the firm engineers and lawyers call when a bridge cracks or a chemical spill raises health questions. The work sits in two niches, engineering failures and environmental health, and it delivers 20 percent profit margins plus 28 percent return on equity while growing revenue at 10 percent a year. Ethical checks clear without issue, so the business itself looks solid and durable.
Yet the opportunity rating sits at none. Shares trade at 22.8 times forward earnings with only an 8 percent margin of safety to our fair value, and three analysts offer no consensus view. That leaves little room for error even though the numbers look respectable on paper.
Currency moves or a slowdown in litigation-driven work could dent growth quickly, and the unknown competitive moat adds another layer of uncertainty. The modest valuation gap does not compensate for those risks in our view. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EXPO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup$77.11+5.4%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$73.15+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$73.15+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$73.15+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$73.15+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$73.15+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$73.15+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup$73.15+1.2%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$72.28+7.4%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter.
2026-10-11Markup · changed$67.30+0.3%Entry 7
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 10%. The street (3 analysts) rates it buy, with a mean price target of $82. Insiders have been net buyers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
